Patents by Inventor David T. Denhardt

David T. Denhardt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Osteopontin Specific Antibodies and Methods of Use Thereof
    Publication number: 20100129376
    Abstract: Monoclonal antibodies immunospecific for osteopontin are disclosed. Also provided are therapeutic methods of use thereof for modulating osteopontin levels for the treatment of autoimmune disorders.
    Type: Application
    Filed: August 24, 2009
    Publication date: May 27, 2010
    Inventors: David T. Denhardt, Lawrence Steinman
  • Osteopontin Specific Antibodies and Methods of Use Thereof
    Publication number: 20090047289
    Abstract: Monoclonal antibodies immunospecific for osteopontin are disclosed. Also provided are therapeutic methods of use thereof for modulating osteopontin levels for the treatment of autoimmune disorders.
    Type: Application
    Filed: August 6, 2008
    Publication date: February 19, 2009
    Inventors: David T. Denhardt, Lawrence Stainman
  • Osteopontin knock-out mouse and methods of use thereof
    Publication number: 20020188962
    Abstract: A transgenic non-human animal with alterations in the osteopontin gene is prepared by introduction of a gene encoding an altered osteopontin protein into a host non-human animal. Methods for using transgenic mice so generated to screen for agents that effect osteopontin's cellular modulating activity are also provided.
    Type: Application
    Filed: July 2, 2002
    Publication date: December 12, 2002
    Inventors: David T. Denhardt, Susan R. Rittling, Masaki Noda, Aaron J. Kowalski
  • Osteopontin knock-out mouse and methods of use thereof
    Patent number: 6414219
    Abstract: A transgenic non-human animal with alterations in the osteopontin gene is prepared by introduction of a gene encoding an altered osteopontin protein into a host non-human animal. Methods for using transgenic mice so generated to screen for agents that effect osteopontin's cellular modulating activity are also provided.
    Type: Grant
    Filed: June 30, 1999
    Date of Patent: July 2, 2002
    Assignee: Rutgers, The State University of New Jersey
    Inventors: David T. Denhardt, Susan R. Rittling, Masaki Noda, Aaron J. Kowalski
  • Suppression of nitric oxide production by osteopontin
    Patent number: 5695761
    Abstract: The present invention relates to compositions and methods for inhibition of the vasoactive and signal transduction agent nitric oxide (NO), and to therapeutic treatment of diseases or disorders that involve inappropriate or detrimental NO activity. The invention particularly relates to modulation of kidney function. In specific embodiments, osteopontin and a 20-amino acid fragment of osteopontin that contains an Arg-Gly-Asp sequence suppress expression of inducible NO synthase mRNA, and osteopontin suppresses the activity of constitutive NO synthase.
    Type: Grant
    Filed: December 23, 1993
    Date of Patent: December 9, 1997
    Assignees: Rutgers University, University of Medicine & Dentistry of NJ
    Inventors: David T. Denhardt, Shiaw-Min Hwang, Diane Elaine Heck, Cecilia Ang Lopez, Debra L. Laskin, Jeffrey D. Laskin